Tamoxifen is the most widely prescribed endocrine therapy for breast cancer, with more than 7.5 million woman-years of clinical experience. Tamoxifen has both antiestrogenic and estrogenic activity. The antiestrogenic activity
Vasilios J. Assikis, MD
Advertisement
Articles by Vasilios J. Assikis, MD
Advertisement
Latest Updated Articles
- Risks and Benefits of Tamoxifen Therapy
Published: February 1st 1997 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
2
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
3
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
4
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
5
